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e DSM-5 has renamed the syndrome De
r (DDD).a b s t r a c t
Case reports and an open trial have reported promising responses to repetitive transcranial magnetic
stimulation (rTMS) to prefrontal and temporo-parietal sites in patients with depersonalization disorder
(DPD). We recently showed that a single session of rTMS to the ventrolateral prefrontal cortex (VLPFC)
was associated with a reduction in symptoms and increase in physiological arousal. Seven patients with
medication-resistant DSM-IV DPD received up to 20 sessions of right-sided rTMS to the VLPFC for 10
weeks. Stimulation was guided using neuronavigation software based on participants’ individual struc-
tural MRIs, and delivered at 110% of resting motor threshold. A session consisted of 1 Hz repetitive TMS
for 15 min. The primary outcome measure was reduction in depersonalization symptoms on the Cam-
bridge Depersonalization Scale (CDS). Secondary outcomes included scores on the Beck Depression In-
ventory (BDI) and Beck Anxiety Inventory (BAI). 20 sessions of rTMS treatment to right VLPFC sig-
niﬁcantly reduced scores on the CDS by on average 44% (range 2–83.5%). Two patients could be classiﬁed
as “full responders”, four as “partial” and one a non-responder. Response usually occurred within the ﬁrst
6 sessions. There were no signiﬁcant adverse events. A randomized controlled clinical trial of VLPFC rTMS
for DPD is warranted.
& 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Depersonalization/derealization is deﬁned in the DSM-IV as
“persistent or recurrent experiences of feeling detached from, and
as if one is an outside observer of, one's mental processes or body
(e.g., feeling like one is in a dream)” (American Psychiatric Asso-
ciation, 1994).2 More speciﬁcally, depersonalization disorder (DPD)
is characterized by distressing feelings of unreality and alterations
in a person's sense of self (Sierra, 2009). The condition is estimated
to have an incidence rate at around 1% (Lee et al., 2012; Michal
et al., 2009) of the population. It commonly begins around early
adulthood (Baker et al., 2003) and has a tendency to be long-
lasting (Simeon et al., 2003). It can appear as a symptom of other
psychiatric disorders (Sierra et al., 2012), including approximatelyIreland Ltd. This is an open acces
ychiatry, Department of Psy-
Neuroscience, King’s College
K.
id).
personalization/Derealization12% of cases of panic disorder (Simeon et al., 2003). The symptom
of depersonalization is commonly described in patients with
neurological conditions, especially temporal lobe epilepsy (Lam-
bert et al., 2002) and also following substance misuse (Medford
et al., 2003; Simeon et al., 2009). A variety of pharmacological
treatments have been tried (Sierra et al., 2006) but for the most
part have not delivered sufﬁcient signiﬁcant improvement to pa-
tients (Baker et al., 2003; Simeon et al., 2003). Research into
psychological treatments are lacking; however a cognitive beha-
vioral model has been developed (Hunter et al., 2003, 2005).
1.1. rTMS and DPD
There have been two case reports, and one trial reporting the
effects of TMS in DPD. In the ﬁrst 1 Hz repetitive TMS of the dor-
solateral prefrontal cortex was used (Keenan et al., 1999) and this
was reported to have increased the patient's self-awareness and
reduced depersonalization symptoms. In a second case study, a 24
year-old male with comorbid DPD and major depression who had
not responded to pharmacotherapy (Jiménez-Genchi, 2004) was
given left DLPFC rTMS thrice weekly. After six sessions, a 28% re-
duction in symptoms was reported. Finally, a trial in twelve DPDs article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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poral parietal junction (TPJ) TMS after three weeks of treatment
(Mantovani et al., 2011). The TPJ region was chosen due to its re-
levance in out of body experiences (Blanke et al., 2005; Simeon
et al., 2000). Five out of the six responders showed a 68% reduc-
tion in symptoms after a total of six weeks treatment. Un-
fortunately, none of these studies utilized either a sham or active
control condition, so it is not possible to exclude placebo effects.
We have recently explored the effect of rTMS to the ventro-
lateral prefrontal cortex (VLPFC) (Jay et al., 2014). A neurobiolo-
gical model has also been proposed (Sierra and Berrios, 1998),
hypothesizing dysfunctionally increased fronto-insula/limbic in-
hibitory regulation. This model is consistent with neurological case
studies (Lambert et al., 2002) and has been reﬁned by neuroima-
ging research using fMRI (Lemche et al., 2007; Phillips et al., 2001),
which has demonstrated reduced insula, limbic and visual asso-
ciation cortical activation in response to emotive pictures, and
increased VLPFC activation. In the recent study we hypothesized
that inhibition to right VLPFC using low frequency (LF) rTMS
would lead to increased arousal and reduced symptoms (Jay et al.,
2014). Seventeen patients with DPD and healthy controls were
randomized to receive one session of right-sided rTMS to VLPFC or
temporo-parietal junction (TPJ). Patients showed increased elec-
trodermal capacity, suggesting increased physiological arousal
after VLPFC rTMS only, although both groups showed symptomatic
improvements, at least immediately post TMS. We concluded that
TMS is a potential therapeutic option for DPD and that modulation
of VLPFC is a plausible mechanism. Most recently the occurrence
of depersonalization symptoms has been reported following high
frequency (HF), i.e. stimulatory rTMS to the dorsolateral PFC in a
woman with treatment-resistant depression (Geerts et al., 2015)
which is consistent with the model.2. Methods
2.1. Design
This study employed a consecutive ‘case-series’ design with
before and after measures.
2.2. Participants
There were N¼7 participants in total (N¼5 were male) re-
cruited through the Depersonalization Unit Clinic, a specialist
tertiary care outpatients service based at the Maudsley Hospital,
South London. All patients had a primary diagnosis of DPD (DSM
IV-TR) following interview by the clinic psychiatrist. All were given
a copy of an Information Sheet explaining the purpose of the trial
and the basic working of rTMS. Participants were informed that
they were being offered multiple sessions of an off-label experi-
mental treatment and that they could withdraw from the trial at
any time and without giving a reason.
Inclusion criteria included a current primary diagnosis of DPD
with scores Z70 on the Cambridge Depersonalization Scale
(Sierra and Berrios, 2000) and ability to provide written informed-
consent. Exclusion criteria were personal history of migraine or
severe headaches, a current or historical neurological diagnosis, a
personal or family history of seizures, any medical condition in-
volving a loss of consciousness, or contraindications to MRI. All
were unresponsive to at least one medication, although most had
failed to respond to several and had been ill for at least 2 years.
Patients taking medications could participate in the trial if their
medication did not have safety contraindications with rTMS (Rossi
et al., 2009) and if they had been on a stable dose for at least two
weeks. None were currently receiving co-current psychotherapy.A structural MRI was obtained for all participants prior to rTMS.
MRI data were acquired on a GE 1.5 T HDx system (General Elec-
tric, Milwaukee, WI, USA) at the Institute of Psychiatry, London.
Localiser and calibration scans were followed by 2D T2-weighted
Fast Spin Echo and FLAIR (Fluid Attenuated Inversion Recovery)
scans. A 3D T1-weighted Inversion Recovery prepared Spoiled
Gradient Echo (IR-SPGR) scan was then collected with the fol-
lowing parameters: TE¼5 ms; TR¼12 ms; TI¼300 ms; excitation
ﬂip angle¼18°; matrix size 320224220 over a
288202198 Field of View, giving an isotropic 0.9 mm voxel
size over the whole brain. Images were converted to DICOM for-
mat for use within BrainSight 2, a widely used neuronavigation
software program (Herwig et al., 2001) which ensures that sti-
mulation can only be delivered when the target site is positioned
using the frameless stereotaxy.
2.3. TMS protocol
Resting motor threshold (MT) in M1, deﬁned as the lowest in-
tensity of TMS which yielded motor-evoked potentials (MEPs) of at
least 50 mV in 5 out of 10 trials using an MEP pod, was determined
from electromyographic (EMG) activity in the abductor pollicis
brevis using surface electrodes. Co-registration of the participant
with their MRI scan and BrainSight 2 (Rogue Research, Montreal),
and coil calibration were performed. The ‘target site’ of right VLPFC
for stimulation using the Simple Point method was prepared prior
to the participant's arrival by entering their Talairach coordinates.
The coordinates (x¼35, y¼25, z¼7) were chosen to correspond
to Brodmann Area (BA) 47 (which were previously found to be
active in only patients with a diagnosis of DPD in response to
aversive scenes in an fMRI task (Phillips et al., 2001)). The coil was
held tangential to the scalp of the head with the handle pointing
back away from midline at 45°. Each session participants received
15 min rTMS delivered at 1 Hz and 110% MT to the right VLPFC
using a Magstim RMA6802, 3014-00 Rapid2 Dual PSU ﬁgure-of-
eight coil (Magstim Co. Ltd., UK) – i.e. 900 pulses per session.
Following TMS, outcome measures were completed plus a side-
effects checklist.
2.4. Outcome measures
Socio-demographic variables were recorded for all participants.
At baseline, all participants completed the CDS, a self-assessment
instrument with good reliability and validity which has state and
trait versions (CDS-S and CDS-T, respectively). A score of 70 (out of
maximum 290, CDS-T) has a sensitivity of 75.5% and speciﬁcity of
87.2% as a clinical cut-off (Sierra and Berrios, 2000). The CDS-S
adapts 22 of the 29 items which lend themselves to a ‘here and
now’ rating and uses the mean score expressed as a percentage.
While the CDS-T requires scores on a 1–10 Likert scale for each
item (a combination of frequency and duration ratings) and the
total score expressed as a sum, the CDS-S is measured in 1–100%
and the total expressed as a mean value. The scale has high re-
liability and internal consistency and has been shown to be sen-
sitive to symptom change (Hunter et al., 2005). Participants also
completed the Beck Depression Inventory (Beck et al., 1961), Beck
Anxiety Inventory (Beck et al., 1988) and the Dissociative Experi-
ences Scale (Bernstein and Putnam, 1986).
Patients received two sessions weekly, which were evenly
spaced throughout the week for participants’ convenience.
At each session symptoms of depersonalization were measured
using the self-report version of the CDS-S immediately before
and after TMS as well as a safety checklist post rTMS. At the
last session, participants completed a CDS-T, BAI, BDI, and DES as
ﬁnal outcome measures. The CDS-S was the primary outcome
measure.
Table 2
Clinical measures at baseline and post rTMS trial.
Psychopathology ratings pre and post rTMS - (Means (SD))
N¼7
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trative paired t-tests. Response rates were calculated according to
percentage reductions in CDS-S score; reductions on the CDS-S of
at least 50% were classed as a ‘full response’ and reductions of 25%
or more were classed as ‘partial response’ (Mantovani et al., 2011).Pre rTMS End of rTMS
trial
Reduction in % t p
BDI 18.0 (9.0) 15.3 (11.9) 15.0 1.94 40.10
BAI 13.4 (11.8) 9.6 (7.2) 28.4 1.92 40.10
DES 20.2 (11.5) 20.2 (10.5) 0.0 0.19 40.85
Table 3
Response rates and pre/post TMS scores on Cambridge Depersonalization Scale
(CDS) for all 7 cases.
Case CDS – trait
(baseline)
CDS – state
(baseline)
CDS –
state
post-
trial
Reduction on
CDS – state
(%)
Response
post-trial
1 166 36.0 23.8 33.9 Partial
2 110 61.7 10.2 83.5 Full
3 164 32.7 15.2 53.5 Full
4 138 43.6 42.6 2.3 Non
5 83 25.1 13.5 46.2 Partial
6 127 51.2 29.2 42.9 Partial
7 76 19.6 10.1 48.3 Partial
Series
mean
(SD)
123.4 (35.9) 38.6 (14.7) 20.7
(12.0)
44.4 (24.2) n/a3. Results
3.1. Demographic characteristics
Patients 1–7 completed a full course of treatment (i.e., a total of
17–20 sessions). Three of the participants were taking psycho-
tropic medication to include selective-serotonin-reuptake-in-
hibitors with or without the augmentation of lamotrigine (all 46
months). Patients differed little in their age of onset (Table 1).
3.2. Outcome measures
Clinical psychopathology measures at baseline and trial com-
pletion are shown in Tables 2 and 3. Depersonalization symptom
scores (CDS-S) fell by 44.4% overall, although there were large
individual differences in CDS-S score change (range 2.3% to 83.5%)
(see Table 3). Paired t-tests showed that the change in scores was
signiﬁcant (p¼0.03, t¼2.92, df¼6). It appears that anxiety
symptom scores fell somewhat (paired t-tests, NS), whilst scores
on depression and general dissociation symptom measures did not
change. Treatment progress session by session for a single case is
shown in Fig. 2.
Total percentage reductions in CDS-S scores were calculated for
each patient. We used criteria applied in a previous rTMS trial for
DPD (Mantovani et al., 2011). After one session, 5 out of 7 patients
showed a ‘partial response’ according to these criteria, and after
trial completion, 2 out of 7 patients showed a ‘full response’ (see
Table, 3). A paired t-test was signiﬁcant at the 5%-level: t(6)¼2.92,
p¼0.03.
3.2.1. Case vignette
Patient 2: A 40-year-old unemployed male with longstanding
depersonalization, accompanied by low mood and a history of
alcohol misuse. He had neither responded to several prescribed
pharmacotherapies, nor cognitive behavioral therapy. Depersona-
lization began gradually in the context of panic attacks associated
with agoraphobia, which later took on a permanence, replacing
the panic attacks altogether. He felt cut-off from the world, emo-
tionally numb, things appeared unreal, and he experienced feel-
ings of lack of agency, ‘being on auto-pilot’. After the ﬁrst TMS
session the patient described feeling “noticeably more awake and
‘switched on’”. Half way through the second treatment, the patient
experienced feelings of “increased wakefulness” and “being more
cheerful”. Half way through his treatment course the patient
spontaneously reported that on a train journeying back from a
session, the faces of strangers and commuters appeared “threa-
tening”. He also reported increases in hearing clarity and appetite.
One possible negative consequence of TMS treatment was a
transient change in drinking behavior “to calm myself a little”.Table 1
Demographic information for patients in series (n¼7).
Trial participants diagnosed with DPD (Mean, SD)
Age, years 36.1 (12.7)
Gender N¼5 Male: N¼2 Female
Duration of DPD illness, years 19.4 (18.5)
Age of DPD onset, years 16.6 (6.1)
CDS-trait Score 123.4 (35.9)3.3. Adverse and side-effects
All patients completed a side-effects checklist after every rTMS
session encompassing pleasant as well as unpleasant side effects.
Two patients experienced a mild headache. One also experienced
pain above his left eye on two occasions.
Whilst we did not measure disinhibitory behavior directly, on
some occasions patients appeared to display examples of such
behavior immediately after an rTMS session. This included:
(i) putting on the physician's jacket (ii) labile affect (iii) sponta-
neous laughter with no clear origin, and (iv) discussing provoca-
tive subjects spontaneously. Similar examples are referred to in
the rTMS side-effects literature (Wassermann, 1998). None of
these instances were long-lasting or of clinical concern.4. Discussion
Data presented in this case series indicate that 1 Hz rTMS to the
right VLPFC may be a potential treatment option for DPD, which
has previously proved difﬁcult to treat with pharmacotherapy. Six
out of seven participants showed over 25% improvement in
symptoms, two over 50%. One participant did not respond to
treatment.
Key outcome measures in this study were scores on the CDS-S
and other standardized measures, however patients commented
that these scales did not always capture all the phenomenological
changes they were experiencing.
Findings indicate that a single session of right-sided VLPFC 1 Hz
stimulation can reduce scores on the CDS-S, but these scores tend
to fall further following multiple sessions of this treatment (see
Fig. 1). General symptoms of dissociation (DES) were not affected
attesting to the speciﬁcity of the intervention for DPD. Patient
responses are quite individual when examined in detail (see
Fig. 2); 20 sessions may be more than is required for maximum
beneﬁts to be realized with much beneﬁt appearing after the ﬁrst
1–5 sessions.
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Fig. 1. Scores on the CDS (State Version) for Cases 1–7. Mean scores with error bars
(SDs) on the CDS-S for all 7 participants at three time points of the TMS treatment.
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Fig. 2. Scores on the CDS (State Version) for Case 4. Full treatment progression with
TMS giving pre- and post-session scores for Case 4 on the CDS-S. *Please note that
the pre-session score for meeting no. 3 is missing.
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psychotropic medications and as such make it a potentially new
treatment method for the disorder. Multiple sessions of rTMS to
the right VLPFC delivered at 1 Hz is tolerable and acceptable to
patients.
4.1. Limitations
Placebo effect in rTMS treatment is a complex issue ex-
acerbated by the difﬁculty in creating a true sham condition
(Broadbent et al., 2011; Rossi et al., 2009). Our proof of concept
study showed a single session of rTMS to TPJ and VLPFC both re-
duced symptoms although only with the latter was there con-
comitant changes in physiological arousal. This study could be
interpreted as showing the potential value of stimulation to both
sites in the alleviation of DPD, perhaps acting through different
neural circuits or different point of the same circuits (for those for
self-directed attention, or, emotional control (Corbetta and Shul-
man, 2002; Ochsner and Gross, 2005)). However, placebo effects
cannot be ruled out without a sham condition with double-blind
allocation (Broadbent et al., 2011). Hence a deﬁnite therapeutic
effect for rTMS in this condition has not yet been proven. Patients
included in case series studies are often selected because of their
chronicity and their willingness to undergo novel approaches.
Hence the generalizability of any results cannot be assumed. In
addition, no clinician-rated outcome or more regular anxiety
(BAI)/depression (BDI) measures were captured.4.2. Future directions
The potential of rTMS as a treatment option for DPD requires
further study in the form of a controlled trial of multiple sessions
of rTMS. If further sham-controlled research proves positive, rTMS
may be judged an appropriate intervention or adjunct to other
interventions e.g. antidepressants. Combining treatment studies
with investigations of mechanisms using neurophysiological and
neuroimaging techniques for example would also lead to rapid
advances in the ﬁeld. Finally, the optimal delivery of rTMS for
therapeutic purposes such as the spacing and number of sessions
also requires further study.Acknowledgements
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